title: Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.
abstract: BACKGROUND
  There are no established guidelines for pathologic diagnosis/reporting of intraductal papillary mucinous neoplasms (IPMNs).
  
  
  METHODS
  An international multidisciplinary group, brought together by the Verona Pancreas Group in Italy-2013, was tasked to devise recommendations.
  
  
  RESULTS
  (1) Crucial to rule out invasive carcinoma with extensive (if not complete) sampling. (2) Invasive component is to be documented in a full synoptic report including its size, type, grade, and stage. (3) The term "minimally invasive" should be avoided; instead, invasion size with stage and substaging of T1 (1a, b, c; ≤ 0.5, > 0.5-≤ 1, > 1 cm) is to be documented. (4) Largest diameter of the invasion, not the distance from the nearest duct, is to be used. (5) A category of "indeterminate/(suspicious) for invasion" is acceptable for rare cases. (6) The term "malignant" IPMN should be avoided. (7) The highest grade of dysplasia in the non-invasive component is to be documented separately. (8) Lesion size is to be correlated with imaging findings in cysts with rupture. (9) The main duct diameter and, if possible, its involvement are to be documented; however, it is not required to provide main versus branch duct classification in the resected tumor. (10) Subtyping as gastric/intestinal/pancreatobiliary/oncocytic/mixed is of value. (11) Frozen section is to be performed highly selectively, with appreciation of its shortcomings. (12) These principles also apply to other similar tumoral intraepithelial neoplasms (mucinous cystic neoplasms, intra-ampullary, and intra-biliary/cholecystic).
  
  
  CONCLUSIONS
  These recommendations will ensure proper communication of salient tumor characteristics to the management teams, accurate comparison of data between analyses, and development of more effective management algorithms.
authors.affiliation: *Department of Pathology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA †Department of Pathology, Massachusetts General Hospital, Boston, MA ‡Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan §Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY ¶Department of Pathology, University of Verona, Verona, Italy ||Department of Surgery, Massachusetts General Hospital, Boston, MA **Department of Surgery, University of Verona, Verona, Italy ††Department of Surgery, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD ‡‡Departments of Surgery, University of Bonn, Bonn, Germany §§Departments of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands ¶¶Department of Surgery, Edouard Herriot Hospital, HCL, Lyon, France ||||Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands ***Departments of Pathology, Technical University, Munich, Germany †††Department of Pathology, Showa University Fujigaoka Hospital, Yokohama, Japan ‡‡‡Department of Pathology, Tokai University Hachioji Hospital, Tokyo, Japan §§§Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea ¶¶¶Department of Pathology, Pontificia Universidad Católica de Chile, Santiago, Chile ||||||Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY ****Department of Surgery, Massachusetts General Hospital, Boston, MA ††††Department of Surgery, Seoul National University Hospital, Seoul, Korea ‡‡‡‡Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.
authors.forename: Volkan
authors.initials: V
authors.lastname: Adsay
authors.forename: Mari
authors.initials: M
authors.lastname: Mino-Kenudson
authors.forename: Toru
authors.initials: T
authors.lastname: Furukawa
authors.forename: Olca
authors.initials: O
authors.lastname: Basturk
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Zamboni
authors.forename: Giovanni
authors.initials: G
authors.lastname: Marchegiani
authors.forename: Claudio
authors.initials: C
authors.lastname: Bassi
authors.forename: Roberto
authors.initials: R
authors.lastname: Salvia
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Malleo
authors.forename: Salvatore
authors.initials: S
authors.lastname: Paiella
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Wolfgang
authors.forename: Hanno
authors.initials: H
authors.lastname: Matthaei
authors.forename: G Johan
authors.initials: GJ
authors.lastname: Offerhaus
authors.forename: Mustapha
authors.initials: M
authors.lastname: Adham
authors.forename: Marco J
authors.initials: MJ
authors.lastname: Bruno
authors.forename: Michelle D
authors.initials: MD
authors.lastname: Reid
authors.forename: Alyssa
authors.initials: A
authors.lastname: Krasinskas
authors.forename: Günter
authors.initials: G
authors.lastname: Klöppel
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ohike
authors.forename: Takuma
authors.initials: T
authors.lastname: Tajiri
authors.forename: Kee-Taek
authors.initials: KT
authors.lastname: Jang
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Roa
authors.forename: Peter
authors.initials: P
authors.lastname: Allen
authors.forename: Carlos
authors.initials: C
authors.lastname: Fernández-del Castillo
authors.forename: Jin-Young
authors.initials: JY
authors.lastname: Jang
authors.forename: David S
authors.initials: DS
authors.lastname: Klimstra
authors.forename: Ralph H
authors.initials: RH
authors.lastname: Hruban
mesh_terms: D001650:Bile Duct Neoplasms / Q000473:pathology*; D002278:Carcinoma in Situ / Q000473:pathology*; D005568:Forms and Records Control; D006801:Humans; D008499:Medical Records; D010190:Pancreatic Neoplasms / Q000473:pathology*